Horizon adds gout drug with Crealta acquisition
Horizon Pharma plc plans to acquire Crealta Holdings LLC for $510 million in cash. Horizon said the deal will bring the company Krystexxa (pegloticase), the first and only Food and Drug Administration-approved drug for chronic refractory gout.